Stock·NASDAQ·Healthcare
GE HealthCare Technologies Inc. (GEHC)
- Market cap
- $32.00B
- P/E
- 15.81
- Dividend yield
- 0.21%
- Street target
- $84.00median of 21 analysts
- 52-week range
- $58.75 $89.77
The short version
Where GEHC stands today, in four lines, and what CleaRank Financial AI makes of it.
GEHC at a glance
GE HealthCare Technologies Inc. (GEHC): Buy, 76/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($68.61 and $70.54).
- Insiders Insiders bought $6.4M and made no open-market sales over the last 18 months.
- Valuation P/E of 15.8 against 31.9 for the Healthcare sector: a discount to peers (-50%).
Figures as of October 16, 2026.
CleaRank Financial AI
GE HealthCare Technologies Inc. (GEHC) is trading at $70.35, below its 200-day simple moving average of $70.54 but above its 50-day SMA of $68.61 and 20-day EMA of $66.76.
The company's recent earnings report for February 4, 2026, showed EPS of $1.44, beating estimates by 2.86%, though the stock saw a slight decline of 0.39% on the news. Insiders have been net buyers, with $6.4 million in purchases versus no reported sales, indicating moderate accumulation. Wall Street analysts maintain a positive outlook, with a consensus rating of Buy and a median price target of $84.00, suggesting a potential upside of 19.4%. The company is expected to grow revenue by approximately 5.00% for the current year and 5.00% for the next year.
Only on CleaRank
Figures we compute ourselves from GEHC's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $70.35 is 2.5% above the 50-day simple moving average of $68.61.Price above its 200-day average ›
The price is 0.3% below the 200-day simple moving average of $70.54.50-day average above the 200-day ›
The 50-day average ($68.61) is 2.7% below the 200-day average ($70.54), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 37% of its 52-week range, between $58.75 and $89.77.
GEHC share price
Pick a period: each tab shows how far GEHC has moved over it, to the last close.
Today's trading
Where GEHC sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 15.81 is 50.4% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 1.50 is 55.7% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $2.0B on revenue of $21.3B, a net margin of 9.3%.Pays a dividend ›
The trailing dividend yield is 0.21%, or $0.145 a share a year.
Key statistics
The headline figures for GEHC.
As of October 16, 2026, GEHC trades at $70.35, with a market value of $32.00B, a P/E ratio of 15.81 and a dividend yield of 0.21%.
What the numbers say
CleaRank Financial AI's reading of GEHC's valuation, growth and risks.
GE HealthCare Technologies Inc. (GEHC) exhibits a P/E ratio of 15.81, which is significantly below the healthcare sector median of 31.9, suggesting a potential valuation discount.
Its price-to-sales ratio is 1.50, also below the sector average of 3.4. The company's return on equity is a strong 19.38%, considerably higher than the sector median of 7.3%. With a profit margin of 9.33% and an operating margin of 14.98%, GEHC demonstrates solid profitability. The debt-to-equity ratio stands at 0.94, which is in line with the sector median. The company's revenue growth of 5.8% for the current year is slightly below the sector average of 8.1%, but the positive profitability and lower valuation multiples present a favorable fundamental picture.
GEHC against the Healthcare sector
How GEHC compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: GEHC trades at a notable discount to sector peers (-50%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 5, 2025, GEHC has gained 1.4% against a gain of 28.9% for XLV.
Performance against XLV
GEHC and the Healthcare sector fund over the same days.
Revenue and earnings
How much GEHC sells, and how much of it becomes profit.
Revenue growth: Revenue grew 4.8% in FY2025 to $20.6B, from $19.7B a year earlier.
Profit margin: The net margin was 10.4% in FY2025, up from 10.4% the year before.
Profitable: GEHC earned $2.2B in FY2025.
Earnings reality check
Did GEHC beat what analysts expected, and how did the stock react?
Earnings record: GEHC beat the analyst estimate in 1 of the last 1 quarters.
Market reaction: The stock fell in the first session after 1 of those 1 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Feb 4, 2026after close | $1.40 | $1.44 | +2.86% | -0.39% | -4.15% |
Reports after February 4, 2026 are not yet in our data.
As of October 16, 2026, GEHC has beaten the analyst EPS estimate in 1 of its last 1 reported quarters and fell in the first trading session after it; its most recent report in our data, on February 4, 2026, came in 2.86% above the estimate and the stock moved -0.39% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 65.1, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 65.1 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of GEHC
The score, the reasoning behind it, and what could move the price next.
GE HealthCare Technologies Inc. (GEHC) is currently trading above its 50-day SMA ($68.61) and 20-day EMA ($66.76), indicating short-term positive momentum, although it remains below its 200-day SMA ($70.54).
The 14-day RSI is at 65.06, signaling bullish momentum, and the MACD is positive at 0.26. The nearest support is the 50-day SMA at $68.61, while resistance is near the 200-day SMA at $70.54 and the current price. Volume on the latest trading day was 3.75 million, slightly below the average of 3.89 million, suggesting a moderate level of investor interest. The stock's position above key short-term moving averages, coupled with bullish RSI momentum, suggests a potential for upward movement if it can decisively break above the 200-day SMA. However, trading below the longer-term average indicates a need for sustained buying pressure to confirm a stronger trend.
Moderate Insider Buying Activity ›
Insiders have purchased $6.4 million worth of GE HealthCare Technologies Inc. (GEHC) stock with no reported sales, indicating strong internal confidence.
Source: Insider Trading DataPositive Analyst Sentiment and Price Targets ›
21 Wall Street analysts cover GEHC, with a consensus 'Buy' rating and a median price target of $84.00, implying a 19.4% upside potential.
Source: Wall Street AnalystsBullish Technical Momentum ›
The 14-day RSI is at 65.06, signaling bullish momentum, and the stock is trading above its 50-day SMA and 20-day EMA.
Source: Technical AnalysisEarnings Beat on Recent Report ›
GEHC reported EPS of $1.44 on February 4, 2026, beating estimates by 2.86%, demonstrating operational execution.
Source: Earnings Report
Trading Below 200-Day SMA ›
GEHC is currently trading below its 200-day simple moving average of $70.54, indicating potential resistance and a need for sustained buying to confirm a longer-term uptrend.
Source: Technical Analysis
- Consider the moderate insider buying totaling $6.4 million as a signal of management confidence in GE HealthCare Technologies Inc. (GEHC)'s future prospects.
- GE HealthCare Technologies Inc. (GEHC) is trading above its 50-day SMA and 20-day EMA, indicating short-term strength, but remains below its 200-day SMA, suggesting potential resistance at higher levels.
- With a dividend yield of 0.21%, GE HealthCare Technologies Inc. (GEHC) offers a modest income stream, which may appeal to income-focused investors, though capital appreciation appears to be the primary driver for this stock.
Technical indicators
Momentum and trend for GEHC, from its daily closes.
As of October 16, 2026, with GEHC at $70.35, its 14-day RSI is 65.1 (showing bullish momentum without being overbought), its 50-day simple moving average is $68.61 and its 200-day is $70.54.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What GEHC moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, GEHC's 1-year correlation of daily returns is +0.51 with S&P 500 (SPY), +0.39 with Nasdaq 100 (QQQ), +0.08 with Bitcoin (BTC) and +0.06 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
16 of 21 analysts rate it a buy or strong buy, 5 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $84.00 is 19.4% above the price.More buy ratings than three months ago ›
16 of 21 rate it a buy now, against 14 of 19 three months ago.
GEHC Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Initiates | Overweight |
| Oct 5, 2026 | Citigroup | Maintains | Neutral |
| Oct 5, 2026 | Needham | Reiterates | Buy |
| Sep 22, 2026 | Needham | Initiates | Buy |
| Sep 17, 2026 | BTIG | Reiterates | Buy |
| Aug 19, 2026 | BTIG | Reiterates | Buy |
As of October 16, 2026, 21 Wall Street analysts cover GEHC: 16 rate it a buy or strong buy, 5 a hold and 0 a sell or strong sell. Their 12-month price targets range from $70.00 to $96.00, with a median of $84.00, 19.4% above the price of $70.35.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
GEHC trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from GEHC's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much GEHC tends to move, against the market and on its own.
The long record
GEHC's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 1.55% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 35.3%, from February 2025 to April 2025; the price is still 24.5% below that peak.Most 1-year holds ended higher ›
37% of 1-year holding periods in the last 3 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in July 2023 is now worth $9,132.05, against $17,629 in the S&P 500 (SPY).
GEHC Drawdowns & Recovery
As of October 16, 2026, GEHC's worst peak-to-trough fall over the last 3 years with dividends reinvested was -35.3% (February 2025 to April 2025); it is still 24.5% below that peak, and 37% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into GEHC in July 2023 is worth now, against the same amount in the S&P 500.
Against the market: GEHC trailed the S&P 500 over this period: $9,132.05 against $17,629.
A $10,000 investment in GEHC in July 2023 would be worth about $9,132 today with dividends reinvested, compared with about $17,629 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to GEHC, and which have not.
Strongest month, February: an average of +9.65%, up in 2 of 3 years.
Weakest month, March: an average of -8.89%, up in 0 of 3 years.
This month, October: has averaged -3.47%, up in 1 of 3 years. Past seasonality does not repeat on schedule.
Over the last 4 years, GEHC's strongest calendar month has been February (average +9.65%, up in 2 of 3 years) and its weakest March (average -8.89%, up in 0 of 3 years).
Average return for each calendar month over the last 4 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in GEHC, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in GEHC today could grow to about $14,326 by 2036 in the base case, with a 90th-percentile outcome near $54,700 and a 10th-percentile outcome around $3,752. The simulation models price only; at today's 0.21% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
GEHC Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $81.23 for GEHC by 2030 in the base case, from $70.35 today (1.2x over 4 years). The 10th-percentile path ends near $34.81. These are outcomes of a Monte Carlo simulation run on GEHC's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $47.74 | $72.93 | $111 | |
| 2028 | $41.52 | $75.59 | $138 | |
| 2029 | $37.62 | $78.36 | $163 | |
| 2030 | $34.81 | $81.23 | $190 | |
| 2031 | $32.65 | $84.20 | $217 |
Method: a lognormal simulation of GEHC's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
GEHC insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $6.4M on the open market.
As of October 16, 2026, GEHC insiders reported no open-market sales and 8 open-market purchases worth $6.4M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | William K. Grogan
Chief Financial Officer
|
Grant | 75.1K | - |
| May 22, 2026 | Kevin A Lobo
Director
|
Buy | 10.0K | $641.8K |
| May 12, 2026 | Rodney F Hochman
Director
|
Buy | 1.6K | $100.4K |
| May 8, 2026 | Watkin Phoebe L Yang
Director
|
Buy | 1.0K | $63.0K |
| May 7, 2026 | Henry Lawrence Culp Jr.
Director
|
Grant | 7.7K | - |
| May 7, 2026 | Rodney F Hochman
Director
|
Grant | 6.3K | - |
| May 7, 2026 | Catherine Anne Lesjak
Director
|
Grant | 3.6K | - |
| May 7, 2026 | Kevin A Lobo
Director
|
Grant | 3.6K | - |
| May 7, 2026 | Anne T Madden
Director
|
Grant | 5.9K | - |
| May 7, 2026 | William J Stromberg
Director
|
Grant | 3.6K | - |
| May 7, 2026 | Watkin Phoebe L Yang
Director
|
Grant | 3.6K | - |
| May 6, 2026 | Henry Lawrence Culp Jr.
Director
|
Buy | 80.8K | $5.0M |
| May 6, 2026 | William J Stromberg
Director
|
Buy | 1.0K | $61.7K |
| May 1, 2026 | James Saccaro
Chief Financial Officer
|
Buy | 3.3K | $200.6K |
| Apr 30, 2026 | Peter J Arduini
Chief Executive Officer
|
Buy | 4.2K | $249.8K |
| Apr 30, 2026 | Frank R Jimenez
General Counsel
|
Buy | 1.8K | $105.8K |
| Mar 13, 2026 | Kevin A Lobo
Director
|
Grant | 777 | - |
| Mar 2, 2026 | Peter J Arduini
Chief Executive Officer
|
Grant | 49.1K | - |
| Mar 2, 2026 | Jeannette Bankes
Officer
|
Grant | 6.9K | - |
| Mar 2, 2026 | Adam Y Holton
Officer
|
Grant | 5.5K | - |
| Mar 2, 2026 | Frank R Jimenez
General Counsel
|
Grant | 10.9K | - |
| Mar 2, 2026 | Taha Kass-Hout
Chief Technology Officer
|
Grant | 13.3K | - |
| Mar 2, 2026 | George A. Newcomb
Officer
|
Grant | 1.3K | - |
| Mar 2, 2026 | Kevin Michael O'Neill
Officer
|
Grant | 6.5K | - |
| Mar 2, 2026 | Philip Rackliffe
Officer
|
Grant | 9.4K | - |
| Mar 2, 2026 | Roland Rott
Officer
|
Grant | 8.6K | - |
| Mar 2, 2026 | James Saccaro
Chief Financial Officer
|
Grant | 12.5K | - |
| Feb 12, 2026 | Peter J Arduini
Chief Executive Officer
|
Grant | 74.9K | - |
| Feb 12, 2026 | Frank R Jimenez
General Counsel
|
Grant | 22.1K | - |
| Feb 12, 2026 | Taha Kass-Hout
Chief Technology Officer
|
Grant | 23.3K | - |
| Feb 12, 2026 | George A. Newcomb
Officer
|
Grant | 2.5K | - |
| Feb 12, 2026 | Kevin Michael O'Neill
Officer
|
Grant | 6.9K | - |
| Feb 12, 2026 | Philip Rackliffe
Officer
|
Grant | 3.2K | - |
| Feb 12, 2026 | Roland Rott
Officer
|
Grant | 7.9K | - |
| Feb 12, 2026 | James Saccaro
Chief Financial Officer
|
Grant | 22.6K | - |
| Sep 11, 2025 | Roland Rott
Officer
|
Option | 5.3K | $298.6K |
| Aug 15, 2025 | Kenneth Robert Stacherski
Officer
|
Grant | 10.2K | - |
| May 28, 2025 | Henry Lawrence Culp Jr.
Director
|
Grant | 6.7K | - |
| May 28, 2025 | Rodney F Hochman
Director
|
Grant | 4.8K | - |
| May 28, 2025 | Lloyd Howell Jr
Director
|
Grant | 3.1K | - |
| May 28, 2025 | Risa J Lavizzo-Mourey
Director
|
Grant | 3.1K | - |
| May 28, 2025 | Catherine Anne Lesjak
Director
|
Grant | 3.1K | - |
| May 28, 2025 | Anne T Madden
Director
|
Grant | 4.8K | - |
| May 28, 2025 | Tomislav Mihaljevic
Director
|
Grant | 3.1K | - |
| May 28, 2025 | William J Stromberg
Director
|
Grant | 5.1K | - |
| May 28, 2025 | Watkin Phoebe L Yang
Director
|
Grant | 3.1K | - |
| May 15, 2025 | Jeannette Bankes
Officer
|
Grant | 37.0K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.